Thermo Fisher Expects 7% Annual Organic Revenue Growth Over Long Term
By Nicholas G. Miller
Thermo Fisher Scientific expects to record 7% annual organic revenue growth and low-teens adjusted-earnings-per-share growth over the long term.
The company, which is hosting its investor day Wednesday, said its market has improving demand trends and strong long-term growth fundamentals.
It also said AI will be a long-term driver of growth by accelerating scientific breakthroughs and improving returns on drug discovery, thereby fueling additional investment into Thermo Fisher customers' drug pipelines.
Write to Nicholas G. Miller at nicholas.miller@wsj.com
(END) Dow Jones Newswires
May 20, 2026 09:05 ET (13:05 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
